Novartis Abandons Heart Drug After Surprising Failure in Key Study
Novartis AG is halting development of pelacarsen, an experimental heart drug, after a key study showed no benefit in preventing heart attacks or cardiovascular deaths. The drug, which targets Lp(a), a cholesterol-carrying particle, failed to reduce heart attacks or strokes despite lowering Lp(a) levels. Novartis will continue one trial for a heart valve disease. The company has another experimental drug, DII235, in midstage testing.
How this was made
The 30-second read
Why it matters
The negative trial result removes a potential blockbuster from Novartis' pipeline, likely prompting a short‑term sell‑off and prompting analysts to reassess the company's cardiovascular franchise.
Market read
The announcement is a primary disclosure of a failed Phase 3 trial, a material event for a large pharma company, and is expected to affect its stock price and the broader cardiovascular biotech space.
What to watch
The trial still demonstrated strong Lp(a) reduction, which could be valuable in earlier‑stage or preventive‑population studies.
Background
Novartis' pelacarsen was a leading candidate targeting Lp(a), a genetically determined cholesterol particle linked to heart disease. The failure was presented at the American Heart Association meeting.
Ticker impact
Novartis announced it is largely abandoning pelacarsen after a key trial showed no benefit in preventing heart attacks or cardiovascular deaths.
downward pressure as investors price in the lack of efficacy and potential write‑off of development costs
Clinical‑trial failure for a high‑profile cardiovascular drug removes a potential revenue stream and signals a setback for the Lp(a) program.
Market effects
May dampen enthusiasm for Lp(a)‑lowering programs across the biotech sector.
Limited to markets where Novartis and other large pharma stocks trade.
Modest; the news is specific to Novartis but could influence investor sentiment toward cardiovascular‑focused biotech pipelines.
Counterpoint
Some investors may view the setback as a buying opportunity if they believe the remaining siRNA program (DII235) still holds upside.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant developing pelacarsen.
